$PSYC the company announced the release of a speci
Post# of 144498
(Total Views: 160)
Posted On: 08/27/2020 1:23:08 PM
$PSYC the company announced the release of a special edition of its Microdose Monthly newsletter featuring an exclusive interview conducted by PSYC CEO, David Flores, and long-time psilocybin therapy advocates and Chief Petitioners of Initiative Petition 34 (“IP 34”) in the state of Oregon, Tom and Sheri Eckert.
Distributed this morning to Microdose Monthly subscribers, and now live on the Psychedelic Spotlight website under Spotlight Originals, the interview highlights the recent accomplishment of the IP 34 campaign team, guided, and led by chief architects, Tom and Sheri Eckert, in helping to secure the nearly 165,000 signatures required to place the initiative on the ballot in Oregon this November and providing Oregonians with the opportunity to potentially green light a state licensed and regulated psilocybin therapy program within the state.
According to data provided by Mental Health America, Oregon is currently ranked as one of the worst/bottom states in the U.S. in terms of its prevalence of mental health illnesses and disorders amongst its residents in addition to significantly lower rates of access to care when compared to other states. Such conditions, compounded by the recent COVID-19 pandemic, have created a significant mental health epidemic within the state and particularly for those struggling with a variety of illnesses and disorders such as depression, anxiety, and addiction. Based on encouraging data from research and studies performed by leading medical research institutions such as Johns Hopkins, UCLA, and NYU, Psilocybin therapy through IP 34 aims to provide Oregonians with a much needed alternative to conventional, and mostly pharma-based drugs, whereby placing more emphasis on treatment over management.
Distributed this morning to Microdose Monthly subscribers, and now live on the Psychedelic Spotlight website under Spotlight Originals, the interview highlights the recent accomplishment of the IP 34 campaign team, guided, and led by chief architects, Tom and Sheri Eckert, in helping to secure the nearly 165,000 signatures required to place the initiative on the ballot in Oregon this November and providing Oregonians with the opportunity to potentially green light a state licensed and regulated psilocybin therapy program within the state.
According to data provided by Mental Health America, Oregon is currently ranked as one of the worst/bottom states in the U.S. in terms of its prevalence of mental health illnesses and disorders amongst its residents in addition to significantly lower rates of access to care when compared to other states. Such conditions, compounded by the recent COVID-19 pandemic, have created a significant mental health epidemic within the state and particularly for those struggling with a variety of illnesses and disorders such as depression, anxiety, and addiction. Based on encouraging data from research and studies performed by leading medical research institutions such as Johns Hopkins, UCLA, and NYU, Psilocybin therapy through IP 34 aims to provide Oregonians with a much needed alternative to conventional, and mostly pharma-based drugs, whereby placing more emphasis on treatment over management.
(0)
(0)Scroll down for more posts ▼